Structural insight for cancer care
Aventa clinical tests use Arima’s Hi-C sequencing technology to detect clinically relevant fusions and rearrangements from routine FFPE tumor tissue, the sample type most commonly available in cancer care. By bringing structural genome analysis into clinical testing workflows, Aventa helps clinicians find more answers, refine diagnoses, and guide therapy selection.
Aventa FusionPlus
Aventa FusionPlus detects clinically relevant fusions and rearrangements from routine FFPE solid tumor tissue, including events that can be missed or incompletely characterized by conventional workflows.
Therapy selection
Eligibility for fusion-directed therapies is commonly determined by DNA and/or RNA sequencing. These methods are powerful, but clinically relevant fusions and rearrangements can be missed when detection depends on breakpoint coverage, transcript expression, RNA quality, or recovery of an informative fusion transcript.
For patients whose tumors remain driver-negative after standard genomic profiling, Aventa FusionPlus provides a structure-based way to identify treatment-relevant fusions and rearrangements.
Diagnosis and classification
In certain solid tumors, accurate diagnosis and patient management can depend on identifying characteristic recurrent rearrangements.
These rearrangements are often evaluated through FISH workflows that may require multiple rounds of testing. Those workflows can consume limited tissue and still leave the clinically relevant rearrangement missed or incompletely characterized.
Aventa FusionPlus enables broad, structure-based detection of clinically relevant fusions and rearrangements in a single test, supporting diagnosis and classification in fusion-driven or diagnostically challenging solid tumors.
Aventa Lymphoma
Structural insight for lymphoma
Aventa Lymphoma is designed for lymphoma, where rearrangements can shape diagnosis, classification, prognosis, and treatment planning. In lymphoma, the question is often not only whether a gene is rearranged, but how the event is structured and what partner is involved.
FISH remains important in lymphoma diagnostics, but it is inherently targeted. It evaluates selected loci and probe patterns, often one question at a time, potentially leaving clinically important structural findings unresolved.
Aventa Lymphoma uses Hi-C sequencing to detect rearrangements through the structural relationships they create in the genome, not through predefined probe placement. By providing a broader rearrangement view, Aventa Lymphoma can help clarify findings that affect diagnosis, classification, prognosis, treatment planning, or clinical trial consideration.